Abstract LB473: JNJ-95437446: Discovery and preclinical characterization of an amivantamab-based EGFR/MET-ADC for solid tumor indications

Key Points

• To evaluate the efficacy and safety of JNJ-95437446, an EGFR/MET bispecific antibody drug conjugate.
• Evaluated JNJ-95437446 in preclinical models of solid tumors including NSCLC, colorectal, and head & neck carcinomas.
• Assessed pharmacokinetic properties and stability of linker/payload in multiple tests.
• Conducted safety assessments in GLP NHP studies across various doses.
• Demonstrated potent, target-dependent cytotoxicity in vitro with rapid internalization.
• Achieved complete tumor regressions in NSCLC xenograft models resistant to amivantamab.
• Showed favorable safety profile with strong tolerability in GLP NHP studies.

Abstract